Jennifer Brogdon | Director of Exploratory Immuno Oncology
N.I.B.R. | United States

Jennifer Brogdon, Director of Exploratory Immuno Oncology, N.I.B.R.

Dr. Jennifer Brogdon is currently Director of Exploratory Immuno-Oncology at Novartis Institute for Biomedical Research, and has been instrumental in building the company’s preclinical CAR (chimeric antigen receptor) T cell therapy program for Oncology, which includes leading the research collaboration with the University of Pennsylvania and leading an internal, cross-functional group to develop the next generation of CAR therapy programs.  Since she joined NIBR in 2004, Dr. Brogdon has led global project teams and made significant contributions to antibody and cell & gene therapy drug discovery programs from discovery to IND filing to participation in the BLA submission and approval of Kymriah, a novel, personalized T cell therapy for B cell malignancies.  
In addition to the CAR pipeline responsibilities, she is actively engaged in other Immuno-Oncology therapeutic programs, Due Diligence efforts and has made significant contributions to a variety of publications and patent applications. Dr. Brogdon holds a PhD in Immunology from Duke University and completed her postdoctoral training at Yale University.

Appearances:



DC Co-conference Day 3 April 5 @ 09:10

Panel: Engineering CAR-T & TCR cells for cancer therapy

  • How can you additionally modify T-cells beyond the T cell receptor/ the CAR to behave in a more controlled and/or potent fashion?
  • The challenge of keeping the manufacturing process simple, whilst maintaining the effectiveness of the product
  • The use of molecular imaging to track CAR T cells: Where do they go in the body? Do they accumulate in the tumor?
  • Mitigating side effects: controlling neurotoxicity etc.
  • Biomarkers – Identifying patients that will respond to treatment
  • Combination strategies

back to speakers